Brokers Issue Forecasts for Intra-Cellular Therapies, Inc.’s FY2025 Earnings (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) – Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for shares of Intra-Cellular Therapies in a research note issued on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will post earnings per share of $0.50 for the year, down from their previous forecast of $0.55. The consensus estimate for Intra-Cellular Therapies’ current full-year earnings is ($0.59) per share.

ITCI has been the subject of a number of other research reports. Royal Bank of Canada lifted their price target on Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an “outperform” rating in a report on Friday, October 4th. UBS Group decreased their target price on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $100.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, August 7th. Mizuho increased their price objective on shares of Intra-Cellular Therapies from $96.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, June 21st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $130.00 target price on shares of Intra-Cellular Therapies in a report on Monday, September 16th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.62.

Intra-Cellular Therapies Trading Up 1.8 %

NASDAQ ITCI opened at $76.09 on Thursday. The firm’s fifty day moving average price is $74.25 and its two-hundred day moving average price is $72.34. Intra-Cellular Therapies has a 1 year low of $45.50 and a 1 year high of $84.89. The firm has a market capitalization of $8.03 billion, a P/E ratio of -65.59 and a beta of 1.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.03. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. The firm had revenue of $161.40 million for the quarter, compared to analyst estimates of $157.74 million. During the same quarter in the previous year, the firm earned ($0.45) EPS. The business’s quarterly revenue was up 45.7% on a year-over-year basis.

Insider Buying and Selling at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 53,013 shares of the stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $80,970,388.85. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, EVP Mark Neumann sold 18,714 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $75.08, for a total value of $1,405,047.12. Following the sale, the executive vice president now directly owns 29,700 shares in the company, valued at approximately $2,229,876. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Sharon Mates sold 53,013 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the transaction, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at approximately $80,970,388.85. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 175,316 shares of company stock valued at $13,037,345 in the last ninety days. 3.40% of the stock is currently owned by company insiders.

Institutional Trading of Intra-Cellular Therapies

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its holdings in Intra-Cellular Therapies by 52.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 578,615 shares of the biopharmaceutical company’s stock worth $41,440,000 after purchasing an additional 199,503 shares in the last quarter. Vanguard Group Inc. boosted its position in Intra-Cellular Therapies by 6.5% during the 4th quarter. Vanguard Group Inc. now owns 9,094,302 shares of the biopharmaceutical company’s stock worth $651,334,000 after buying an additional 554,577 shares during the period. HighPoint Advisor Group LLC bought a new stake in Intra-Cellular Therapies during the 4th quarter worth approximately $217,000. Kapitalo Investimentos Ltda acquired a new position in Intra-Cellular Therapies in the 4th quarter valued at approximately $26,000. Finally, Hennion & Walsh Asset Management Inc. raised its stake in shares of Intra-Cellular Therapies by 14.4% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 16,651 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 2,090 shares during the last quarter. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.